SG11201907023UA - Method of reducing neutropenia - Google Patents
Method of reducing neutropeniaInfo
- Publication number
- SG11201907023UA SG11201907023UA SG11201907023UA SG11201907023UA SG11201907023UA SG 11201907023U A SG11201907023U A SG 11201907023UA SG 11201907023U A SG11201907023U A SG 11201907023UA SG 11201907023U A SG11201907023U A SG 11201907023UA SG 11201907023U A SG11201907023U A SG 11201907023UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- floor
- new york
- street
- pct
- Prior art date
Links
- 208000004235 neutropenia Diseases 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 abstract 2
- 229950011498 plinabulin Drugs 0.000 abstract 2
- 240000008213 Brosimum alicastrum Species 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000005828 ramon Nutrition 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIPO I PCT (51) International Patent Classification: A61K 31/40 (2006.01) A61K 31/337 (2006.01) A61K 31/04 (2006.01) A61P 35/00 (2006.01) A61K 31/496 (2006.01) (21) International Application Number: PCT/US2018/016498 (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/453,375 01 February 2017 (01.02.2017) US 62/621,533 24 January 2018 (24.01.2018) US (71) Applicant: BEYONDSPRING PHARMACEUTICALS, INC. [US/US]; 28 Liberty Street, 39th Floor, New York, NY 10005 (US). (72) Inventors: MOHANLAL, Ramon; 28 Liberty Street, 39th Floor, New York, NY 10005 (US). HUANG, Lan; 28 Liberty Street, 39th Floor, New York, NY 10005 (US). LLOYD, George, Kenneth; 28 Liberty Street, 39th Floor, New York, NY 10005 (US). (74) Agent: FULLER, Michael, L.; Knobbe, Martens, Olson & Bear, Llp, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 1-1 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 71' IN Published: 71' 71' — with international search report (Art. 21(3)) 00 1-1 (54) Title: METHOD OF REDUCING NEUTROPENIA (57) : Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel 0 induced neutropenia using plinabulin. o mono °noI0 DIDHoHoIID100 OIIIIII (10) International Publication Number WO 2018/144764 Al 01 February 2018 (01.02.2018) English English
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453375P | 2017-02-01 | 2017-02-01 | |
| US201862621533P | 2018-01-24 | 2018-01-24 | |
| PCT/US2018/016498 WO2018144764A1 (en) | 2017-02-01 | 2018-02-01 | Method of reducing neutropenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907023UA true SG11201907023UA (en) | 2019-08-27 |
Family
ID=63040105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907023UA SG11201907023UA (en) | 2017-02-01 | 2018-02-01 | Method of reducing neutropenia |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11400086B2 (en) |
| EP (1) | EP3576733A4 (en) |
| JP (2) | JP2020514412A (en) |
| KR (1) | KR20190109479A (en) |
| CN (1) | CN110381938A (en) |
| AU (1) | AU2018217120B2 (en) |
| BR (1) | BR112019015974A2 (en) |
| CA (1) | CA3052190A1 (en) |
| CL (1) | CL2019002127A1 (en) |
| IL (1) | IL268305B1 (en) |
| MX (2) | MX2019009020A (en) |
| PH (1) | PH12019501763A1 (en) |
| SG (1) | SG11201907023UA (en) |
| WO (1) | WO2018144764A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2728796C2 (en) | 2015-03-06 | 2020-07-31 | Бейондспринг Фармасьютикалс, Инк. | Method for treating a brain tumor |
| CN107530341B (en) | 2015-03-06 | 2021-10-01 | 大连万春布林医药有限公司 | Methods of treating cancers associated with RAS mutations |
| SG10202108194XA (en) | 2015-07-13 | 2021-09-29 | Beyondspring Pharmaceuticals Inc | Plinabulin compositions |
| CA3013467A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| BR112018074990A2 (en) | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composition, uses and method for reducing neutropenia |
| US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| EP3576733A4 (en) | 2017-02-01 | 2020-11-25 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
| WO2019147615A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| CA3089391A1 (en) * | 2018-02-01 | 2019-08-08 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
| US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| CN113613654B (en) * | 2019-10-15 | 2024-01-26 | 大连万春布林医药有限公司 | Application of plinabulin in preparation of medicine for increasing haptoglobin of non-metastatic breast cancer patient |
| CA3189970A1 (en) * | 2020-08-18 | 2022-02-24 | Spectrum Pharmaceuticals, Inc. | Novel methods of treating neutropenia using g-csf protein complex |
| WO2023274316A1 (en) * | 2021-06-29 | 2023-01-05 | 深圳华泓海洋生物医药有限公司 | Application of deuterated plinabulin in preparing drug for treating neutropenia |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS509164B1 (en) | 1970-12-29 | 1975-04-10 | ||
| IT1193786B (en) | 1980-12-18 | 1988-08-24 | Wellcome Found | ETHEREAL COMPOUNDS EQUIPPED WITH MITIGATING ACTIVITY OF INTERMEDIATE HEMOGLOBINOPATHIES AND PROCEDURE FOR THEIR PREPARATION |
| JPS58167304A (en) | 1982-03-24 | 1983-10-03 | 松下電器産業株式会社 | Refuse disposal plant |
| AU576322B2 (en) | 1983-07-22 | 1988-08-25 | Ici Australia Limited | Alpha-substituted-alpha-cyanomethyl alcohols |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| JPH05255106A (en) | 1990-10-31 | 1993-10-05 | Toray Ind Inc | Medicine for thrombocytopenia |
| GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
| US6096786A (en) | 1992-10-01 | 2000-08-01 | Glaxo Wellcome Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
| DK0609606T3 (en) | 1992-10-01 | 1997-03-17 | Wellcome Found | |
| US5872151A (en) | 1992-10-01 | 1999-02-16 | Glaxo Wellcome Inc. | Immunopotentiatory agents and physiologically acceptable salts thereof |
| ES2119996T3 (en) | 1992-11-27 | 1998-10-16 | Napro Biotherapeutics Inc | INJECTABLE COMPOSITION INCLUDING FACLITAXEL. |
| JPH0725858A (en) | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | Piperazine derivative |
| US5958980A (en) | 1993-08-26 | 1999-09-28 | Glaxo Wellcome, Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
| IL110787A0 (en) | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
| GB9402809D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| JP3131574B2 (en) | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | Novel antitumor substance, microorganism and method for producing the substance, and cell cycle inhibitor and antitumor agent containing the substance as active ingredient |
| US5939098A (en) | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| DE69842004D1 (en) | 1997-11-21 | 2010-12-30 | Purdue Neuroscience Co | SUBSTITUTED 2-AMINOACETAMIDES AND APPLICATION THEREOF |
| PL342254A1 (en) | 1998-01-29 | 2001-06-04 | Aventis Pharm Prod Inc | Method of obtaining n-[(aliphatic or aromatic substituend)carbonyl)]-2-aminacetamide and cyclised compound |
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US6069146A (en) | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
| AU752005B2 (en) | 1998-03-26 | 2002-09-05 | Shionogi & Co., Ltd. | Indole derivatives with antiviral activity |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| FR2784988B1 (en) | 1998-10-23 | 2002-09-20 | Adir | NOVEL DIHYDRO AND TETRAHYDROQUINOLEINIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US7026322B2 (en) | 1998-11-12 | 2006-04-11 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| US6358957B1 (en) | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| PT1210428E (en) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, a receptor for b7-4, and uses therefor |
| IL148021A0 (en) | 1999-08-23 | 2002-09-12 | Dana Farber Cancer Inst Inc | Novel b7-4 molecules and uses therefor |
| CA2392477A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| AU782917C (en) | 2000-01-18 | 2006-11-23 | Beyondspring Pharmaceuticals, Inc. | Cell division inhibitors and process for producing the same |
| JP2003528068A (en) | 2000-03-17 | 2003-09-24 | コリクサ コーポレイション | New amphiphilic aldehydes and their use as adjuvants and immune effectors |
| HUP0302358A3 (en) | 2000-05-09 | 2007-09-28 | Adpharma | Piperazinedione compounds and use of them for producing pharmaceutical compositions |
| US6583143B2 (en) | 2000-12-28 | 2003-06-24 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| US20030082140A1 (en) | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
| AU2003213673A1 (en) | 2002-03-01 | 2003-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| IL165214A0 (en) * | 2002-05-17 | 2005-12-18 | Aventis Pharma Sa | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| CN100540548C (en) | 2002-08-02 | 2009-09-16 | 尼瑞斯药品公司 | Synthesizing of dehydrophenylahistin and analogue thereof and dehydrophenylahistin and analogue thereof |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| CN1753912B (en) | 2002-12-23 | 2011-11-02 | 惠氏公司 | Antibodies against PD-1 and uses therefor |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| AU2005212399B2 (en) | 2004-02-04 | 2011-09-22 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| WO2005100364A1 (en) | 2004-04-19 | 2005-10-27 | Krka, Tovarna Zdravil, D.D. Novo Mesto | Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i |
| DE202004018940U1 (en) | 2004-12-07 | 2006-04-13 | Asf Verwaltungs Gmbh | Snap closure, snap-fastener tape and resealable bag |
| CN109485727A (en) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody |
| DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| WO2007035841A1 (en) | 2005-09-21 | 2007-03-29 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| ES2521679T3 (en) | 2006-01-18 | 2014-11-13 | Merck Patent Gmbh | Specific therapy using integrin ligands for cancer treatment |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| WO2008100598A2 (en) | 2007-02-15 | 2008-08-21 | Mannkind Corporation | A method for enhancing t cell response |
| CN101678078B (en) | 2007-04-13 | 2014-12-10 | 阿布拉西斯生物科学公司 | SPARC and methods of use thereof |
| US20090170837A1 (en) | 2007-08-17 | 2009-07-02 | Thallion Pharmaceuticals Inc. | Methods for treating ras driven cancer in a subject |
| ES2558568T3 (en) | 2008-01-08 | 2016-02-05 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
| TWI461423B (en) | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases |
| BRPI0917592B1 (en) | 2008-12-09 | 2021-08-17 | Genentech, Inc | ANTI-PD-L1 ANTIBODY, COMPOSITION, MANUFACTURED ARTICLES AND USES OF A COMPOSITION |
| WO2010083439A2 (en) | 2009-01-16 | 2010-07-22 | Teva Biopharmaceuticals Usa, Inc. | Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia |
| WO2010114922A1 (en) | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| US8999934B2 (en) | 2009-08-10 | 2015-04-07 | Board Of Regents, The University Of Texas System | Treatment of astrocytes-tumor cells inhibitors of endothelin receptors |
| AU2010295646B2 (en) | 2009-09-15 | 2016-02-11 | Ellipses Pharma Limited | Treatment of cancer |
| US20110274723A1 (en) | 2009-10-23 | 2011-11-10 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| RS56469B1 (en) | 2009-11-24 | 2018-01-31 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| CN101766815B (en) | 2009-12-31 | 2012-04-25 | 胡松华 | Application of taxol and taxotere |
| WO2011109625A1 (en) | 2010-03-03 | 2011-09-09 | Targeted Molecular Diagnostics, Llc | Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification |
| US20130064831A1 (en) | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| WO2011151423A1 (en) | 2010-06-04 | 2011-12-08 | Exonhit S.A. | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| JP2012033526A (en) | 2010-07-28 | 2012-02-16 | Fuji Electric Co Ltd | Thin film solar cell and method for manufacturing the same |
| WO2012035436A1 (en) | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| WO2012074904A2 (en) | 2010-11-29 | 2012-06-07 | Precision Therapeutics, Inc. | Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents |
| TWI386203B (en) | 2011-01-07 | 2013-02-21 | Univ China Medical | Pharmaceutical composition for treating brain cancer or reducing temozolomide-resistance of brain cancer cells and uses of the same |
| KR101970025B1 (en) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Antibodies and other molecules that bind b7-h1 and pd-1 |
| WO2013078537A1 (en) | 2011-11-28 | 2013-06-06 | National Research Council Of Canada | Paclitaxel response markers for cancer |
| US20150004175A1 (en) | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
| SG11201407340YA (en) | 2012-05-09 | 2014-12-30 | Cantex Pharmaceuticals Inc | Treatment of myelosuppression |
| AU2013204313C1 (en) | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
| EP2903616B8 (en) * | 2012-10-04 | 2018-02-07 | AB Science | Use of masitinib in combination with gemcitabine for treating a subgroup of patients suffering from pancreatic cancer |
| US10034939B2 (en) | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| EP3626741A1 (en) | 2013-02-20 | 2020-03-25 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP2968536B1 (en) | 2013-03-13 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| JP6526627B2 (en) | 2013-04-24 | 2019-06-05 | テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド | Magnetic resonance map for tissue analysis |
| SG11201509742QA (en) | 2013-06-03 | 2015-12-30 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| CA2918035C (en) * | 2013-07-12 | 2023-01-03 | Knopp Biosciences Llc | Use of dexpramipexole in the treatment of disorders associated with elevated levels of eosinophils and/or basophils |
| AU2013402794B2 (en) | 2013-10-11 | 2020-02-27 | Beyondspring Inc. | Cancer treatment with combination of plinabulin and taxane |
| EP3065772A4 (en) | 2013-11-05 | 2017-09-13 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| ES2923942T3 (en) | 2013-11-06 | 2022-10-03 | Us Health | Procedure for the subtyping of lymphoma types by means of expression profiles |
| CN104796448B (en) | 2014-01-22 | 2019-02-12 | 腾讯科技（深圳）有限公司 | The data processing method and device of network system |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CN106794246B (en) | 2014-08-08 | 2021-10-15 | OncoQuest制药有限公司 | Tumor antigen specific antibodies and TLR3 stimulation to enhance checkpoint interference performance of cancer therapy |
| MY193968A (en) | 2015-02-12 | 2022-11-03 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| CN107530341B (en) | 2015-03-06 | 2021-10-01 | 大连万春布林医药有限公司 | Methods of treating cancers associated with RAS mutations |
| RU2728796C2 (en) | 2015-03-06 | 2020-07-31 | Бейондспринг Фармасьютикалс, Инк. | Method for treating a brain tumor |
| WO2016165007A1 (en) | 2015-04-17 | 2016-10-20 | The University Of British Columbia | Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer |
| SG10202108194XA (en) | 2015-07-13 | 2021-09-29 | Beyondspring Pharmaceuticals Inc | Plinabulin compositions |
| CA2996426A1 (en) | 2015-10-05 | 2017-04-13 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| CA3013467A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| BR112018074990A2 (en) | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composition, uses and method for reducing neutropenia |
| US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| EP3576733A4 (en) | 2017-02-01 | 2020-11-25 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
| JP7280192B2 (en) | 2017-03-13 | 2023-05-23 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Plinabulin composition and use thereof |
| WO2019147615A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| CA3089391A1 (en) | 2018-02-01 | 2019-08-08 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
| CA3101612A1 (en) | 2018-06-01 | 2019-12-05 | Beyondspring Pharmaceuticals, Inc. | Composition and method of treating cancer associated with egfr mutation |
| CA3109223A1 (en) | 2018-08-16 | 2020-02-20 | Beyondspring Pharmaceuticals, Inc. | Method and composition for stimulating immune response |
-
2018
- 2018-02-01 EP EP18747593.4A patent/EP3576733A4/en active Pending
- 2018-02-01 SG SG11201907023UA patent/SG11201907023UA/en unknown
- 2018-02-01 CN CN201880015615.8A patent/CN110381938A/en active Pending
- 2018-02-01 IL IL268305A patent/IL268305B1/en unknown
- 2018-02-01 US US16/482,547 patent/US11400086B2/en active Active
- 2018-02-01 WO PCT/US2018/016498 patent/WO2018144764A1/en unknown
- 2018-02-01 MX MX2019009020A patent/MX2019009020A/en unknown
- 2018-02-01 CA CA3052190A patent/CA3052190A1/en active Pending
- 2018-02-01 KR KR1020197024588A patent/KR20190109479A/en not_active Application Discontinuation
- 2018-02-01 BR BR112019015974-6A patent/BR112019015974A2/en unknown
- 2018-02-01 JP JP2019562251A patent/JP2020514412A/en active Pending
- 2018-02-01 AU AU2018217120A patent/AU2018217120B2/en active Active
-
2019
- 2019-07-30 PH PH12019501763A patent/PH12019501763A1/en unknown
- 2019-07-30 CL CL2019002127A patent/CL2019002127A1/en unknown
- 2019-07-30 MX MX2022010805A patent/MX2022010805A/en unknown
-
2022
- 2022-07-29 US US17/877,198 patent/US20220378784A1/en active Pending
- 2022-10-25 JP JP2022170658A patent/JP2022191484A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3576733A4 (en) | 2020-11-25 |
| CL2019002127A1 (en) | 2019-12-13 |
| WO2018144764A1 (en) | 2018-08-09 |
| JP2020514412A (en) | 2020-05-21 |
| KR20190109479A (en) | 2019-09-25 |
| PH12019501763A1 (en) | 2020-03-16 |
| US20200038395A1 (en) | 2020-02-06 |
| EP3576733A1 (en) | 2019-12-11 |
| NZ755858A (en) | 2021-11-26 |
| IL268305B1 (en) | 2024-04-01 |
| US20220378784A1 (en) | 2022-12-01 |
| IL268305A (en) | 2019-09-26 |
| CA3052190A1 (en) | 2018-08-09 |
| AU2018217120A1 (en) | 2019-08-15 |
| CN110381938A (en) | 2019-10-25 |
| RU2019125489A3 (en) | 2021-10-25 |
| BR112019015974A2 (en) | 2020-03-31 |
| JP2022191484A (en) | 2022-12-27 |
| RU2019125489A (en) | 2021-03-02 |
| US11400086B2 (en) | 2022-08-02 |
| MX2022010805A (en) | 2022-09-27 |
| MX2019009020A (en) | 2019-11-12 |
| AU2018217120B2 (en) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201804811WA (en) | Fenfluramine compositions and methods of preparing the same | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer |